Portal de Periódicos da CAPES

Anti-interleukin-17 treatment of psoriasis

2016; Informa; Volume: 27; Issue: 4 Linguagem: Inglês

10.3109/09546634.2015.1115816

1471-1753

Sphoorthi Jinna, Bruce Strober,

Asthma and respiratory diseases

AbstractPsoriasis is a chronic, immune-mediated, inflammatory dermatosis, affecting 2–3% of the US population. While first-generation cytokine antagonists targeting tumor necrosis factor alpha (TNF-α)-dependent pathways have produced favorable responses in the treatment of psoriasis, higher levels of efficacy in a greater proportion of patients have been shown in trials with antibodies targeting interleukin (IL)-17A and the IL-17 receptor subunit. This examines the role of IL-17 inhibitors in the treatment of plaque psoriasis. The efficacy and safety results from the phase-3 trials with monoclonal antibodies targeting IL-17RA (brodalumab) and IL-17A (ixekizumab and secukinumab) validate IL-17 as a highly effective therapeutic target for the treatment of plaque psoriasis.KeywordsBrodalumabixekizumabIL-17psoriasissecukinumab Declaration of interestSphoorthi Jinna reports no conflicts of interest.Dr. Strober has received honoraria for serving as a consultant, advisory board member, and/or speaker for AbbVie, Amgen, Astra Zeneca, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Forward Pharma, Janssen, Leo, Maruho, Medac, Novartis, Pfizer, Stiefel/GlaxoSmithKline, Sun, and UCB; has received payments (to the University of Connecticut) as an investigator for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis, Xenoport, and Xoma; has received fees as a scientific director for the CORRONA Psoriasis Registry; and has received grant support (to the University of Connecticut for Fellowship Program) from AbbVie and Janssen.